Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic Inc (IMUX) is a clinical-stage biopharmaceutical company pioneering oral therapies for chronic inflammatory and autoimmune diseases. This page serves as the definitive source for Immunic's latest developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on key programs like IMU-838 for multiple sclerosis, IMU-935 for psoriasis, and IMU-856 targeting gastrointestinal disorders. Our news collection covers essential updates including FDA communications, trial result publications, and scientific conference presentations.
Bookmark this page to efficiently track Immunic's progress in advancing selective immunomodulation therapies while maintaining accessibility for both professional investors and those new to understand the company's pipeline.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in three key industry conferences this July focused on immunology therapies. From July 5-6, members will attend the 3rd FORUM Science & Health: Medicine of the Future in Fürstenfeldbruck, Germany. Notably, Evelyn Peelen, Ph.D., will present findings on IMU-935, an oral IL-17 inhibitor, at the 16th World Immune Regulation Meeting from July 6-9 in Davos, Switzerland. Additionally, Dr. Peelen will discuss IMU-935 at the B & T Cell-Mediated Autoimmune Disease Drug Development Summit from July 26-28 in Boston.
On June 15, 2022, Immunic, Inc. (Nasdaq: IMUX) announced the publication of positive results from its phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (RRMS). The study demonstrated that treatment significantly reduced MRI lesion counts by 62% and 70% for 45 mg and 30 mg doses, respectively, compared to placebo. The drug was found to be safe and well-tolerated, with no significant adverse effects. Following these findings, Immunic is progressing with its phase 2 CALLIPER trial and phase 3 ENSURE program, aiming to explore further potential of vidofludimus.
Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on oral immunology therapies for chronic inflammatory and autoimmune diseases, announced its participation in several conferences this June. Highlights include a presentation on IMU-935, a novel oral IL-17 inhibitor, at the 13th International Congress on Autoimmunity from June 10-13 in Athens, Greece. The company will also hold meetings during the BIO International Convention in San Diego from June 12-16 and participate in the JMP Securities Life Sciences Conference on June 15-16 in New York.
Immunic reported results from its phase 2 CALDOSE-1 trial of vidofludimus calcium (IMU-838) for ulcerative colitis, which failed to meet the primary endpoint of clinical remission. Unexpected interference with corticosteroids was noted, where patients on steroids showed lower remission rates. The company will not pursue further UC development independently and will focus on ongoing multiple sclerosis trials instead. As of May 31, 2022, Immunic reported $93.1 million in cash, projected to last until Q4 2023.
Immunic, Inc. (Nasdaq: IMUX) announced its Q1 2022 financial results, reporting a net loss of $20.8 million ($0.74 per share), down from a loss of $34.5 million in Q1 2021. Research and development expenses increased to $17.4 million, while general and administrative expenses rose to $4.0 million. The company expects its cash reserves of $95.7 million will fund operations into Q3 2023. Notable clinical milestones include upcoming top-line data from the Phase 2 CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis, expected next month.
Immunic, Inc. (Nasdaq: IMUX) announced the initiation of Part C in its ongoing phase 1 clinical trial of IMU-856, aimed at treating celiac disease. This milestone marks the inclusion of 42 patients in a double-blind, placebo-controlled study focusing on the safety and tolerability of IMU-856, which is an orally available small molecule modulator. Preclinical data suggest its potential to restore intestinal barrier function. The company anticipates sharing full safety data later this year. Celiac disease affects 1 in 100 individuals globally, highlighting a critical need for effective treatments.
Immunic, Inc. (Nasdaq: IMUX) will announce its financial results for the first quarter ending March 31, 2022, on May 10, 2022, before market opening. A webcast will follow at 8:00 am ET. The company develops selective oral therapies for chronic inflammatory and autoimmune diseases, with ongoing programs targeting diseases such as multiple sclerosis and ulcerative colitis. This release also includes a corporate update and highlights the company’s significant development pipeline. Archived webcast will be available post-event.
Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on immunology therapies for chronic diseases, will participate in key investor and industry conferences. Upcoming events include the B. Riley Securities' Neuro & Ophthalmology Conference (April 27-28), where CEO Daniel Vitt will speak, and the Outsourcing in Clinical Trials Europe (May 4-5) in Barcelona. Additionally, the company will present at Bio€quity Europe (May 16-18 and May 23-24) and attend the Digestive Disease Week (May 21-24) in San Diego. Details of the events and presentations can be found on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) announced the promotion of Glenn Whaley, CPA, to the role of Chief Financial Officer, effective immediately. Whaley, who joined Immunic in 2019 and has held various finance roles, is recognized for his expertise and contributions to the company's financial operations. The CEO, Daniel Vitt, expressed confidence in Whaley's leadership as the company prepares for crucial data readouts from its lead product candidates, vidofludimus calcium and IMU-935, expected later this year. The company focuses on developing therapies for chronic inflammatory diseases.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on immunology therapies, will participate in several key conferences in March 2022. Notably, Duane Nash, Chairman of the Board, will engage in a fireside chat at the 34th Annual Roth Conference on March 15 in Dana Point, CA. Other conferences include Clinical Trial Supply Europe in Madrid and the American Academy of Dermatology Annual Meeting in Boston. The company's lead drug, IMU-838, targets autoimmune diseases. For updates, visit www.imux.com.
